R-3750

Phase 1Small molecule

RRise Therapeutics LLC

R-3750 is one of 51 small molecule programs targeting Crohn Disease (CD). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Crohn Disease (CD)Not yet recruiting

Ulcerative ColitisRecruiting

Crohn Disease (CD)Phase 1

Not yet recruiting

Ulcerative ColitisPhase 1

Recruiting

Competition

Competitive Landscape

104 competitors in Ulcerative Colitis

#DrugCompanyPhaseTrials

Humira

Novartis

Phase 3

19 2

Stelara

Johnson & Johnson

Phase 3

11 3

Velsipity

Pfizer

Phase 3

10 4

Jyseleca

Gilead

Phase 3

6 5

Skyrizi

AbbVie

Phase 3

6 6

Tremfya

Johnson & Johnson

Phase 3

2 7

Mounjaro

Eli Lilly

Phase 3

1 8

Mesalazine

Ferring

Phase 3

17 9

Atorvastatin Calcium

Merck & Co.

Phase 2

1 10

Zasocitinib

Takeda

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Ulcerative Colitis

NCT05666960

Q4 2028

Phase 1Not yet recruiting

COPD

NCT07076290

Q1 2029

Phase 1Not yet recruiting

Crohn Disease (CD)

NCT07791888

Clinical

Trials by Indication[1]

Ulcerative Colitis1 trial

R-3750 in Patients With Mild to Moderate Ulcerative Colitis

Recruiting·RRise Therapeutics LLC·Phase 1·NCT05666960·36 enrolled

COPD1 trial

A Repeat Ascending Dosing Study of the Safety and Clinical Activity of R-3750 in Patients With Mild to Moderate COPD

Not yet recruiting·RRise Therapeutics LLC·Phase 1·NCT07076290·27 enrolled

Crohn Disease (CD)1 trial

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Clinical Activity, and Pharmacodynamic Effects of R-3750 in Patients With Crohn's Disease

Not yet recruiting·RRise Therapeutics LLC·Phase 1·NCT07791888·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for R-3750. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — R-3750 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for R-3750. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rise Therapeutics LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: RRise Therapeutics LLC

R-3750

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2028

Q1 2029

Trials by Indication[1]

Ulcerative Colitis1 trial

COPD1 trial

Crohn Disease (CD)1 trial

References

Drug Info

Quick Facts

Related News